Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleClinical Investigation

Qualitative and Quantitative Impact of Protective Glucocorticoid Therapy on the Effective 131I Half-Life in Radioiodine Therapy for Graves Disease

Hubertus Hautzel, Elisabeth Pisar, Nahid Yazdan-Doust, Matthias Schott, Markus Beu and Hans-Wilhelm Müller
Journal of Nuclear Medicine December 2010, 51 (12) 1917-1922; DOI: https://doi.org/10.2967/jnumed.110.080473
Hubertus Hautzel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elisabeth Pisar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nahid Yazdan-Doust
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthias Schott
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Markus Beu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hans-Wilhelm Müller
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 51 no. 12 1917-1922
DOI 
https://doi.org/10.2967/jnumed.110.080473
PubMed 
21078788

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication June 23, 2010
  • Accepted for publication August 30, 2010
  • Published online November 23, 2010.

Article Versions

  • previous version (November 15, 2010 - 05:49).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2010 by Society of Nuclear Medicine

Author Information

  1. Hubertus Hautzel1,2,
  2. Elisabeth Pisar1,2,
  3. Nahid Yazdan-Doust1,2,
  4. Matthias Schott3,
  5. Markus Beu1 and
  6. Hans-Wilhelm Müller1,2
  1. 1Department of Nuclear Medicine, University of Düsseldorf, Düsseldorf, Germany
  2. 2Department of Nuclear Medicine (KME), Research Center Jülich, Jülich, Germany
  3. 3Department of Endocrinology, Diabetes and Rheumatology, Medical Faculty, University of Düsseldorf, Düsseldorf, Germany
  1. For correspondence or reprints contact: Hubertus Hautzel, Department of Nuclear Medicine (KME), Heinrich-Heine-University Dusseldorf, Forschungszentrum Juelich, Leo-Brandt-Strasse, 52426 Jülich, Germany. E-mail: h.hautzel{at}fz-juelich.de
View Full Text

Statistics from Altmetric.com

Cited By...

  • 12 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Radioiodine Therapy in Benign Thyroid Diseases: Effects, Side Effects, and Factors Affecting Therapeutic Outcome
    Steen Joop Bonnema, Laszlo Hegedüs
    Endocrine Reviews 2012 33 6
  • What Is the Best Definitive Treatment for Graves’ Disease? A Systematic Review of the Existing Literature
    Bradley M. Genovese, Salem I. Noureldine, Elizabeth M. Gleeson, Ralph P. Tufano, Emad Kandil
    Annals of Surgical Oncology 2013 20 2
  • Calculation of therapeutic activity of radioiodine in Graves’ disease by means of Marinelli’s formula, using technetium (99mTc) scintigraphy
    Piotr Szumowski, Małgorzata Mojsak, Saeid Abdelrazek, Monika Sykała, Anna Amelian-Fiłonowicz, Dorota Jurgilewicz, Janusz Myśliwiec
    Endocrine 2016 54 3
  • Euthyroid Graves’ orbitopathy and incidental papillary thyroid microcarcinoma
    Eugen Melcescu, William B. Horton, Karen T. Pitman, Vani Vijayakumar, Christian A. Koch
    Hormones 2013 12 2
  • Prediction of thyroidal 131I effective half-life in patients with Graves' disease
    Ruiguo Zhang, Guizhi Zhang, Renfei Wang, Jian Tan, Yajing He, Zhaowei Meng
    Oncotarget 2017 8 46
  • Radiation Safety Precautions in 131I Therapy of Graves' Disease Based on Actual Biokinetic Measurements
    Bin Liu, Rong Tian, Weiai Peng, Ying He, Rui Huang, Anren Kuang
    The Journal of Clinical Endocrinology & Metabolism 2015 100 8
  • Multifactor Analysis of Thyroid Stiffness in Graves Disease: A Preliminary Study
    Shimei Li, Jiyi Yao, Shaoyun Hao, Xinchuan Zhou, Ningyi Jiang, Xinbao Zhao, Hui Zhi
    American Journal of Roentgenology 2019 212 5
  • An upper cervical cord compression secondary to occult follicular thyroid carcinoma metastases successfully treated with multiple radioiodine therapies
    Ping Dong, Ni Chen, Lin Li, Rui Huang
    Medicine 2017 96 41
  • Focus on radioiodine-131 biokinetics: the influence of methylprednisolone on intratherapeutic effective half-life of 131I during radioiodine therapy of Graves’ disease
    C. Happel, W. T. Kranert, D. Gröner, J. Baumgarten, J. Halstenberg, B. Bockisch, A. Sabet, F. Grünwald
    Endocrine 2021 73 1
  • Effects of Antioxidant Supplementation on Graves’ Disease: A Meta-Analysis
    Qi Song, Xiaoxue Ji, Ying Xie, Keiko Hosohata
    Journal of Clinical Pharmacy and Therapeutics 2023 2023

Article usage

Article usage: November 2010 to April 2025

AbstractFullPdf
Nov 20101441373
Dec 20108668167
Jan 2011455270
Feb 2011224435
Mar 2011384962
Apr 2011142827
May 2011202728
Jun 2011771930
Jul 2011701819
Aug 2011652234
Sep 2011581630
Oct 2011902936
Nov 2011972125
Dec 2011724724
Jan 2012342830
Feb 2012343526
Mar 2012613530
Apr 2012492626
May 2012632217
Jun 2012882628
Jul 2012461810
Aug 2012421210
Sep 2012762820
Oct 2012543634
Nov 2012472022
Dec 2012532219
Jan 2013443617
Feb 2013603617
Mar 2013383014
Apr 2013291619
May 2013432522
Jun 20133099
Jul 2013181518
Aug 201334911
Sep 20131278
Oct 20132444
Nov 20132778
Dec 201331612
Jan 2014331016
Feb 2014411320
Mar 2014281316
Apr 201427714
May 2014121012
Jun 2014956
Jul 2014171215
Aug 2014101814
Sep 2014552323
Oct 2014262310
Nov 201417413
Dec 20142277
Jan 2015121717
Feb 20151783
Mar 201529118
Apr 20152187
May 2015271212
Jun 201520178
Jul 2015222115
Aug 201527177
Sep 20151693
Oct 201512115
Nov 201530129
Dec 201536111
Jan 2016381211
Feb 201630614
Mar 201623820
Apr 201623713
May 2016202019
Jun 201635159
Jul 20161442
Aug 201623108
Sep 2016232025
Oct 2016221116
Nov 201613510
Dec 2016785
Jan 201710569
Feb 2017611012
Mar 2017191285
Apr 2017141210
May 201714262
Jun 201714960
Jul 201712764
Aug 201723183
Sep 201713122
Oct 201716235
Nov 201717265
Dec 20176130
Jan 201819143
Feb 201810203
Mar 201812242
Apr 201821284
May 201818215
Jun 20188152
Jul 20183102
Aug 2018322
Sep 20188144
Oct 20188255
Nov 201873511
Dec 20185273
Jan 20199196
Feb 2019613
Mar 20195410
Apr 20196612
May 20196105
Jun 20195712
Jul 2019967
Aug 20197712
Sep 2019533
Oct 2019637
Nov 20191366
Dec 20191029
Jan 20208610
Feb 20201226
Mar 20201123
Apr 2020630
May 2020747
Jun 2020322
Jul 20201168
Aug 2020522
Sep 20201564
Oct 2020839
Nov 2020959
Dec 20201154
Jan 2021057
Feb 20217816
Mar 20217106
Apr 202171823
May 20215189
Jun 20213138
Jul 202141211
Aug 202151014
Sep 202121712
Oct 20216816
Nov 202152422
Dec 20217258
Jan 20222126
Feb 202231316
Mar 20226166
Apr 20221155
May 202202111
Jun 202241512
Jul 20220171
Aug 20222116
Sep 202211314
Oct 202211148
Nov 20224115
Dec 20221125
Jan 202321116
Feb 2023472
Mar 202321320
Apr 20231176
May 20236105
Jun 20232136
Jul 20230116
Aug 202351211
Sep 20232710
Oct 20233810
Nov 2023367
Dec 20230205
Jan 20243186
Feb 20246175
Mar 20245425
Apr 202491914
May 202403214
Jun 20244288
Jul 202425711
Aug 20242579
Sep 202432712
Oct 202432911
Nov 2024486
Dec 20241186
Jan 202512314
Feb 20251329
Mar 202503911
Apr 2025512626
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 51 (12)
Journal of Nuclear Medicine
Vol. 51, Issue 12
December 1, 2010
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Qualitative and Quantitative Impact of Protective Glucocorticoid Therapy on the Effective 131I Half-Life in Radioiodine Therapy for Graves Disease
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Qualitative and Quantitative Impact of Protective Glucocorticoid Therapy on the Effective 131I Half-Life in Radioiodine Therapy for Graves Disease
Hubertus Hautzel, Elisabeth Pisar, Nahid Yazdan-Doust, Matthias Schott, Markus Beu, Hans-Wilhelm Müller
Journal of Nuclear Medicine Dec 2010, 51 (12) 1917-1922; DOI: 10.2967/jnumed.110.080473

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Qualitative and Quantitative Impact of Protective Glucocorticoid Therapy on the Effective 131I Half-Life in Radioiodine Therapy for Graves Disease
Hubertus Hautzel, Elisabeth Pisar, Nahid Yazdan-Doust, Matthias Schott, Markus Beu, Hans-Wilhelm Müller
Journal of Nuclear Medicine Dec 2010, 51 (12) 1917-1922; DOI: 10.2967/jnumed.110.080473
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • First-in-Human Study of 18F-Labeled PET Tracer for Glutamate AMPA Receptor [18F]K-40: A Derivative of [11C]K-2
  • Detection of HER2-Low Lesions Using HER2-Targeted PET Imaging in Patients with Metastatic Breast Cancer: A Paired HER2 PET and Tumor Biopsy Analysis
  • [11C]Carfentanil PET Whole-Body Imaging of μ-Opioid Receptors: A First in-Human Study
Show more Clinical Investigation

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire